Stocky turns companies like XVIVO PERFUSION AB XVIVO PERFUS into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. 0RKL.L shows moderate growth momentum (52/100 Growth Compounder) but faces severe structural vulnerabilities—a Vulnerability Index of 100 signals reliance on financial buffer as its primary defense against operational or market stress. Leadership alignment (45/100) lags, and weak value fundamentals (18/100) leave little margin for error. This is a speculative position for patient, risk-tolerant investors only.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for XVIVO PERFUSION AB XVIVO PERFUS:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 55/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates XVIVO PERFUSION AB XVIVO PERFUS (0RKL.L) at 55/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. 0RKL.L shows moderate growth momentum (52/100 Growth Compounder) but faces severe structural vulnerabilities—a Vulnerability Index of 100 signals reliance on financial buffer as its primary defense against operational or market st
0RKL.L's current Stocky Verdict is 55/100, placing it in the "Cautious" band. This composite combines a 52/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for XVIVO PERFUSION AB XVIVO PERFUS yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
XVIVO PERFUSION AB XVIVO PERFUS scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
XVIVO PERFUSION AB XVIVO PERFUS's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to XVIVO PERFUSION AB XVIVO PERFUS.
Sign up free and unlock the full analysis on 0RKL.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 0RKL.L in the app.
